|
Australia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Australia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Australia.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Australian pharmaceutical and healthcare industry.
Competitive intelligence, Australian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Australian market.
The Australia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Australia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Australian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Australia to test other views – a key input for successful budgeting and strategic business planning in the Australian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Australian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Australia.
- Exploit The Latest Competitive Australian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Australia.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Australia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Australia Political SWOT |
| Australia Economic SWOT Analysis |
| Australia Business Environment SWOT |
Chapter - Australia Pharmaceuticals And Healthcare Industry SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q209 |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - Australia - Market Summary |
| Regulatory Regime |
| Table: Priorities Of the Therapeutic Goods Administrations Strategic Plan, 2006-2008 |
| OTC Switching Climate |
| Regional Regulatory Harmonisation |
| Recent Regulatory Developments |
| Intellectual Property Issues |
| Trade Agreements |
| Pricing and Reimbursement |
| Table: Historical PBS Co-payments |
| Price Cuts |
| Additions to Reimbursed Drugs List |
| Products Added To The PBS In November 2007 |
| Table Some Recent Additions to PBS |
| Recent Pricing and Reimbursement Developments |
| Table New PBS Formularies |
| Table: Examples Of Drugs In The New PBS Formularies Classification, September 2007 |
Chapter - Industry Trends and Developments |
| Epidemiology |
| Mental Health Issues |
| Healthcare Reforms |
| E-Health |
| Healthcare Expenditure |
| Prescribing Patterns |
| Table Number of prescribed medications 2006-7 |
| Private Healthcare Insurance |
| Domestic Pharmaceutical Sector |
| Recent Domestic Sector Developments |
| Foreign Industry |
| Recent Foreign Sector Developments |
| Retail Pharmacy Sector |
| Biotechnology and Research |
| Table: Australian Biotech Industry Facts |
| Recent Biotechnology Developments |
| Clinical Trials |
| Medical Devices |
| Table Examples Of Medical Devices Classifications |
| Recent Developments in the Medical Devices Sector |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Australia - Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Australia - Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Economy Facing A Tough 2009 |
| Table: Australia - Economic Activity |
| Prescription Market Forecast |
| Table: Australia - Prescription Market Indicators, Historical Data and Forecasts (AUDmn unless otherwise stated) |
| Patented Drug Market Forecast |
| Table: Australia - Patented Market Data And Forecasts, Historical Data and Forecasts |
| Generics Market Forecasts |
| Table: Australia - Generics Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| Table: Australia - OTC Market Indicators, Historical Data and Forecasts (AUDmn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Table: Australia - Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Australia - Other Healthcare Data And Forecasts, Historical Data and Forecasts |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Pharmacy Over-The-Counter Medicine Sales In Australia (US$) 2007 |
Chapter - Company Profiles |
| Leading Multinationals |
| Pfizer |
| Sanofi-Aventis |
| GlaxoSmithKline |
| Merck Sharp & Dohme (Australia) |
| Novartis |
| Roche |
| AstraZeneca |
| Eli Lilly |
| Indigenous Manufacturers |
| Sigma Pharmaceuticals |
| Australian Pharmaceutical Industries |
| Alphapharm (incorporated into Mylan) |
| Herron Pharmaceuticals |
| Mayne Pharma (Hospira) |
Chapter - Country Snapshot: Australia Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2012 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Australia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s Q209 Pharmaceutical Business Environment Rating matrix for the 15 key countries in Asia Pacific, Australia is considered the third-most attractive pharmaceutical market. The pharmaceutical market is highly advanced but the geographical size of the country (which makes distribution difficult) and its restrictive pricing and reimbursement environment will be among the factors conspiring to keep its compound annual growth rate (CAGR) to a low level of 2.71% in local currency terms through to 2013. Having been valued at around US$7bn in 2008, the market is expected to dip in the 2009-2012 period, before reaching US$7.5bn in 2013. BMI Country Risk team is forecasting a 1.4% contraction of Australia’s 2009 real GDP, as the country contends with the ongoing slump in commodity price, marked slowdowns in private consumption, cooling investment and softening demand from key export markets.
The domestic pharmaceutical industry – which includes a large number of multinationals with direct manufacturing presence – is dominated by the producers of generic medicines. Those companies have benefited from regulations that allow ‘springboarding’ during the term of Australian patents, but have been hampered by the fact that research and development (R&D) extends only to the registration of generics, rather than their manufacture for exports. Consequently, in February 2009, a number of domestic players – including members of the Generic Medicines Industry Association (GMiA) – wrote to the Joint Trade-Subcommittee/Manufacturing for Export, urging the government to improve export conditions for Australian generics.
In the meantime, Aurobindo Pharma Australia, a wholly owned subsidiary of Indian pharmaceutical company Aurobindo Pharma, received approval from Australia's regulatory body for the registration of its heart medicine lisinopril tablets in three strengths. Australian Alchemia reported that an Abbreviated New Drug Application (ANDA) for its fondaparinux sodium was submitted to the US Food and Drug Administration (FDA). Alchemia and its partner Dr Reddy’s Laboratories remain confident of commercial success, as no other generic fondaparinux molecules have been made by competitors to date. In other company news, Swiss Intercell AG announced that its vaccine for the prevention of Japanese Encephalitis (JE) was approved by the Australian authorities, with its launch imminent. The Jespect vaccine will be marketed by Australian CSL Biotherapies, with the two companies expecting US$13mn and US$21mn in 2009 and 2010 sales in the country, respectively.
In other developments, the public healthcare scheme Medicare is due to create a national AUD51.6mn (US$30mn) individual healthcare identifiers system, in partnership with the National E-Health Transition Authority (NEHTA). The Australian Medical Association (AMA) welcomed the development, which is aiming to improve efficiency and ensure that correct information is passed between private practice and hospitals. The database could also be used to monitor prescribing patterns, with recent studies showing that general practitioners (GPs) are already issuing fewer scripts than a decade ago.
|
Australia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |